WuXi Biologics

Linesight’s Life Sciences Benchmarking Yields First Insights

Retrieved on: 
Thursday, April 21, 2022
Consulting, Commercial Building & Real Estate, Manufacturing, Construction & Property, Professional Services, Building Systems, Architecture, Other Science, Engineering, Science, Other Construction & Property, Decision-making, Lang, Benchmarking, Confidentiality, Kite Pharma, Research, Database, Barnes, Lang factor, Biogen, GSK, Data, Program, BMS, Merck, Efficiency, Review, Amgen, CSL Behring, List of life sciences, Commercial, Roche, Forecasting, WuXi Biologics, AstraZeneca, Health care, Intelligence, Oil, Fine chemical, Risk management, Residential area, Hospitality, Organon, Pfizer, Takeda, Resilience, Bayer

Nigel Barnes, Director of Life Sciences, Europe, Linesight said: This is hugely significant for life sciences construction projects, because it shows that the effectiveness of the traditional rule of thumb used to cost and plan future projects is limited.

Key Points: 
  • Nigel Barnes, Director of Life Sciences, Europe, Linesight said: This is hugely significant for life sciences construction projects, because it shows that the effectiveness of the traditional rule of thumb used to cost and plan future projects is limited.
  • The ongoing benchmarking initiative, which formally launched in January 2021, now involves 16 life sciences companies, with six additional organisations having joined the collaboration recently namely; CSL Behring , Resilience , Takeda , Organon , Roche and Thermo Fischer .
  • Linesight runs the global benchmarking initiative on a pro bono basis, and participation is open to any life sciences organisation who is willing to share their project data.
  • Barnes said: Construction projects in the life sciences sector differ greatly from one another, posing a barrier to benchmarking on a project-by-project basis.

WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC

Retrieved on: 
Friday, April 15, 2022
EMA, CEO, Investigational New Drug, WuXi Biologics, IND, Monoclonal antibody, Biologics license application, Achievement, Peptide, NMPA, Contract research organization, Organization, ESG, Patient, Biophysical environment, A-DNA, IND World's Fair Line, Development, PMDA, Solution, U.S. FDA, TGA, FDA, BLA, Blas, Drug discovery, Fine chemical, Pharmaceutical industry, Social, Safety

SINGAPORE, April 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, today announced that the company received the award for Bioprocessing Excellence in Viral Clearance and Safety at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event.

Key Points: 
  • SINGAPORE, April 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, today announced that the company received the award for Bioprocessing Excellence in Viral Clearance and Safety at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event.
  • This marks the second consecutive year that WuXi Bio has received this award from IMAPAC, a leading consulting firm in biopharmaceutical industry.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "Being recognized for two consecutive years by IMAPAC with the Bioprocessing Excellence in Viral Clearance and Safety award is a great honor for our business and employees.
  • The Asia-Pacific Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality.

Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully

Retrieved on: 
Thursday, April 7, 2022
People, Shingles, Innovation, HFMD, Investment, III, HPV, Protein engineering, Board, Adult, Vaccine, Research, General manager, Investor, Philosophy, WuXi Biologics, Industry, Technology, RNA transfection, Cervical cancer, COVID-19, Wuxi, COVID-19 vaccine, Tuberculosis, R, Founder, Patient, Hong Kong Stock Exchange, Property management

HONG KONG, Apr 7, 2022 - (ACN Newswire) - On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange.

Key Points: 
  • HONG KONG, Apr 7, 2022 - (ACN Newswire) - On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange.
  • Recbio is a novel vaccine company driven by independent novel adjuvant technology.
  • As the major institutional investor to Recbio, Legend Capital provides Recbio with multi-faceted support involving corporate governance, business strategy, technical route, R&D resources, management improvement and financial support.
  • Hank Zhou, the Co-Chief Investment Officer of Legend Capital, said: "Congratulations to Recbio and its team led by founder Dr. Liu Yong.

CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration

Retrieved on: 
Tuesday, March 29, 2022
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, IBAT, Heart, MPS II, Haemophilia, Therapy, Liver injury, University of Massachusetts Medical School, University, 2-Bromo-LSD, Glioblastoma, Patient, GBM, Genetic distance, Excoriation disorder, Liver, Research, Biliary atresia, Serum, Sleep, WuXi Biologics, Taiwan, Hepatomegaly, Itch, Food, Cholestatic pruritus, Enterohepatic circulation, Hunter syndrome, CEO, Drug discovery, Frost & Sullivan, MPS, Glycogen storage disease, Breakthrough therapy, PFIC, Liver disease, US Foods, University of Massachusetts, Jaundice, Disorder, Xanthoma, NDA, Alagille syndrome, Primary biliary cholangitis, Lists of diseases, FDA, Spiroplasma mirum, University of Washington School of Medicine, Disease, Pharmaceutical industry, Generic drug, ALAGILLE SYNDROME (ALGS), MARALIXIBAT

CANbridge recently received an acceptance letter for a CAN108 NDA the same indication from Chinas National Medical Products Administration.

Key Points: 
  • CANbridge recently received an acceptance letter for a CAN108 NDA the same indication from Chinas National Medical Products Administration.
  • CANbridge and Mirum Pharmaceuticals signed an exclusive license agreement for the development, commercialization and manufacture, under certain conditions, of maralixibat (CAN108) in Greater China last year.
  • As our first therapeutic under development for rare liver disease, CAN108 deepens our rare disease portfolio and highlights the swiftness of our regulatory progress.
  • Alagille syndrome (ALGS) is a rare autosomal dominant disorder that affects multiple organs, including the liver, heart, bones and eyes.

First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Retrieved on: 
Monday, March 28, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Kidney, Cell, Thrombosis, Heart, MPS II, University of Massachusetts Medical School, University, MAC, Death, 2-Bromo-LSD, Glioblastoma, Degenerative disease, Patient, Pulmonary hypertension, GBM, Peking Union Medical College Hospital, Research, WuXi Biologics, Incidence, C3a, PNH, Hemolysis, PHN, Paroxysmal nocturnal hemoglobinuria, Hunter syndrome, Administration, CEO, C3, Anemia, MPS, C5, Safety, C5a, Steroid, Diagnosis, Glycogen storage disease, C3b, University of Massachusetts, Disorder, CH50, Complement component 5, Lists of diseases, Paroxysmal attack, Medicine, Fatigue, Protein, Spiroplasma mirum, Ravulizumab, Haemophilia, Pharmaceutical industry, Vaccine, Fine chemical, Hematology, CAN106, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), CANBRIDGE PHARMACEUTICALS INC.

CAN106 was previously shown to be safe and well-tolerated, with dose-dependent and linear pharmacokinetic exposure, in a study of healthy volunteers in Singapore.

Key Points: 
  • CAN106 was previously shown to be safe and well-tolerated, with dose-dependent and linear pharmacokinetic exposure, in a study of healthy volunteers in Singapore.
  • Based on these results, Chinas National Medical Products Administration approved the CAN106 Phase 1b/2 trial for the treatment of patients with PNH.
  • CAN106 is a novel, long-acting recombinant human monoclonal antibody that binds to and neutralizes C5, a key component of the complement system.
  • Paroxysmal nocturnal hemoglobinuria (PNH) belongs to a group of fatal and rare disorders that occur when the complement system is dysregulated.

WuXi Biologics Recognized as 2022 Top-Rated ESG Company by Sustainalytics

Retrieved on: 
Monday, March 14, 2022
Industry, Development, Chairperson, Risk, Contract research organization, Research, ESG, WuXi Biologics, Patient, Solution, Social Security Government Pension Offset, CEO, Fine chemical, Pharmaceutical industry, Lithium, Biophysical environment, Sustainalytics, Social

SHANGHAI, March 14, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMOservice company, has been recognized as the Industry Top-Rated Company in 2022 by Sustainalytics, a global provider of Environmental, Social and Governance (ESG) related research, ratings and data.

Key Points: 
  • SHANGHAI, March 14, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMOservice company, has been recognized as the Industry Top-Rated Company in 2022 by Sustainalytics, a global provider of Environmental, Social and Governance (ESG) related research, ratings and data.
  • As the results released in February 2022, WuXi Biologics was assessed as Low Risk by Sustainalytics and ranked top 4% in the industry.
  • Dr. Chris Chen, WuXi Biologics' CEO and Chairperson of the ESG Committee, commented, "We are very proud to receive such a positive rating from Sustainalytics.
  • As a global biologics CRDMO service company, WuXi Biologics has been committed to enabling our partners to discover, develop, and manufacture biologics for the benefit of patients worldwide."

WuXi Biologics Wins CMO Leadership Awards in All Six Core Categories for Fifth Consecutive Year

Retrieved on: 
Wednesday, March 2, 2022
CMO, Patient, Biophysical environment, Pharma, Australian and New Zealand Standard Research Classification, Solution, Therapure BioPharma Inc, Contract research organization, Contract, ESG, Development, ISR, WuXi Biologics, CEO, Leadership, Achievement, Trust, Fine chemical, Social

SHANGHAI, March 1, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all six core categories (i.e., capabilities, compatibility, expertise, reliability, quality and service).

Key Points: 
  • SHANGHAI, March 1, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all six core categories (i.e., capabilities, compatibility, expertise, reliability, quality and service).
  • Besides these CMO awards, WuXi Biologics received additional recognition as the CHAMPION in its Capabilities category, applauding for the company's robust capabilities in offering end-to-end biologics solutions which outperformed the industry standards.
  • In the past decade, Outsourced Pharma and Life Science Leader's CMO Leadership Awards worked withIndustry Standard Research (ISR) to conduct the Contract Manufacturing Quality Benchmarking survey.
  • "WuXi Biologics is very honored to receive the CMO Leadership Awards in all six core categories for the fifth straight year and the CHAMPION designation for the first timein its Capabilities category.

CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

Retrieved on: 
Friday, February 25, 2022
Biotechnology, General Health, Pharmaceutical, Health, MPS II, IBAT, Policy, Lists of diseases, Disorder, Tuba mirum, Glycogen storage disease, Dysplasia, Liver, MPS, NDA, Research, Incidence, University, National Medical Products Administration, Therapy, Biliary atresia, University of Massachusetts Medical School, Growth, GBM, Haemophilia, Time-invariant system, Liver transplantation, University of Massachusetts, Disease, NMPA, New Drug Application, Degenerative disease, Hunter syndrome, Hepatomegaly, Glioblastoma, Cholestatic pruritus, Quality of life, CEO, Jaundice, Alagille syndrome, LSD, Serum, Fatty liver disease, Excoriation disorder, Kidney, Bile, WuXi Biologics, Patient, Enterohepatic circulation, Liver injury, PFIC, Death, Itch, Ageing, Liver disease, FDA, Sleep deprivation, Pharmaceutical industry, Fine chemical, Alagille Syndrome (ALGS), CAN108 (maralixibat), CANbridge Pharmaceuticals Inc., Biotechnology, General Health, Pharmaceutical, Health, Alagille Syndrome (ALGS), CAN108 (maralixibat), CANbridge Pharmaceuticals Inc., ALAGILLE SYNDROME (ALGS), CAN108 (MARALIXIBAT), CANBRIDGE PHARMACEUTICALS INC.

The Early and Pilot Implementation Policy of Boao Lecheng International Medical Tourism Pilot Zone enables Chinese patients to access therapeutics that are available in other parts of the world, thereby improving the quality of life of patients, especially children.

Key Points: 
  • The Early and Pilot Implementation Policy of Boao Lecheng International Medical Tourism Pilot Zone enables Chinese patients to access therapeutics that are available in other parts of the world, thereby improving the quality of life of patients, especially children.
  • CANbridge has the exclusive license to develop and commercialize CAN108 in Greater China for three rare liver disease indications: Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA).
  • The National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for CAN108 for Alagille syndrome in China under priority review.
  • Alagille syndrome (ALGS) is an autosomal dominant multisystem disorder which can lead to end-stage liver disease and death.

CANbridge Pharmaceuticals Appoints Dr. Lan Hu as New Independent Director

Retrieved on: 
Thursday, February 17, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, 2-Bromo-LSD, Anecito T. Pesante Sr. Memorial Hospital Co., Hospital, Patient, Hunter syndrome, Chinese, University of Massachusetts Medical School, CEO, Haemophilia, Chase Bank, Glioblastoma, WuXi Biologics, Spiroplasma mirum, Business administration, MPS, Lists of diseases, University of Massachusetts, Leadership, Therapy, Executive director, Glycogen storage disease, University, Disorder, Degenerative disease, MPS II, Board, JPMorgan Chase, Peking University, Medical school, Research, GBM, Conference, University of Michigan, Non-executive director, Northeast Ohio Medical University, General manager, Medicine, Pharmaceutical industry, Management, Fine chemical, Director

CANbridge Pharmaceuticals, Inc. (CANbridge, stock code 1228.HK), a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that it has appointed Lan Hu, Ph.D. as the independent, nonexecutive Director of the Board of Directors and member of the remuneration committee, effective as of February 16, 2022.

Key Points: 
  • CANbridge Pharmaceuticals, Inc. (CANbridge, stock code 1228.HK), a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that it has appointed Lan Hu, Ph.D. as the independent, nonexecutive Director of the Board of Directors and member of the remuneration committee, effective as of February 16, 2022.
  • I believe that I am joining the CANbridge Board at just right time, as the company moves forward aggressively in developing and commercializing therapeutics that could make a difference to patients, said Lan Hu, Ph.D., Director of the CANbridge Pharmaceuticals Board of Directors.
  • CANbridge Pharmaceuticals Inc. (CANbridge, stock code 1228.HK) is a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology.
  • For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com .

Global Biologics CDMO Market Research Report 2022-2026: Growing Need to Focus on Core Competencies & Strong Research and Development Pipeline of Biologics Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 10, 2022
Health, Biotechnology, HOB GmbH & Co KG, Cayman, Research, Uniloc USA, Inc. v. Microsoft Corp., WuXi Biologics, CDMO, Catalent, Therapy, CAGR, JRS, Pigment, Pharmaceutical industry, Retail, Fine chemical

The "Global Biologics CDMO Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biologics CDMO Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The biologics CDMO market is poised to grow by $8.65 bn during 2022-2026, progressing at a CAGR of 12.20%
    This study identifies the growing need to focus on core competencies as one of the prime reasons driving the biologics CDMO market growth during the next few years.
  • The market is driven by the availability of cost-efficient resources in emerging markets and strong research and development pipeline of biologics therapeutics.
  • The report on the biologics CDMO market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.